Boehringer Ingelheim has signed a global license agreement to use the “enterprise:inmation” industrial information management system from inmation Software.
The license agreement will enable Boehringer Ingelheim to create uniform real-time data infrastructure at all of its production facilities around the globe. Prior to conclusion of the contract Boehringer Ingelheim has tested the software in an in-depth evaluation for several months. In addition, as one of the first users from the pharmaceutical industry, Boehringer Ingelheim will join the advisory board of inmation Software to help further develop the management system to continue to meet the advanced needs of the industry.
The enterprise:inmation industrial information management system enables businesses to acquire system, process and production data in real-time and make them available model-based. It is infinitely scalable, both in terms of data capacity and number of global locations, simply leveraging existing data sources from any location. This enables the integration of all systems with a digital interface such as ERP, MES, DAQ, SCADA, DCS or PLC into a global real-time data backbone. As a result the data from heterogenous systems is pulled into a homogenous database that enables users to access the relevant information required at the appropriate level of detail web-based from anywhere with any device. Once the system is installed, it offers fully automated and centrally controlled software updates without burdensome version migration projects.
“enterprise:inmation is a great way to further advance the digital integration of our pharmaceutical production lines, to reduce costs and make our systems fit for the future. Boehringer Ingelheim and inmation Software are two global leaders based in Germany – this is the beginning of a perfect partnership”, says Klaus Fickinger, Head of Automation Pharma & Data Integrity at Boehringer Ingelheim.
The agreed further development of enterprise:inmation will concentrate on the compatibility of lean TCO and the need of software validation within the pharmaceutical industry. “This industry is strictly regulated by guidelines such as Part 11 of the Food and Drug Administration (FDA) or Good Manufacturing Practice (GMP). These special requirements need to be matched with the strengths of our software, like the low total costs of ownership due to the high level of automation”, says Timo Klingenmeier, CEO of inmation Software GmbH. “Our new global license agreement with Boehringer Ingelheim is a great endorsement of our work so far and starts a strong partnership with a highly experienced partner within the regulated production process industry.”